Multiple Sclerosis Organisations Commit to a Shared Global Research Strategy to Accelerate Cures for MS
Agreement seeks to coordinate resources on the highest potential research
TORONTO, June 14, 2023 (GLOBE NEWSWIRE) -- Multiple sclerosis organisations from Australia, Canada, Denmark, France, Germany, Italy, MS International Federation, Spain, U.K., and U.S. have jointly declare their collective commitment to a global research strategy to cure MS. There are multiple paths to MS cures and this coordination will effectively address knowledge gaps and avoid duplication to speed progress together.
Through the Global Research Strategy Framework the organisations will:
Complete a landscape analysis of MS research funding and infrastructure
Share national research plans and identify specific areas for collaboration and acceleration
Align individual and collective resources on the Global Research Framework
Create new joint initiatives to address strategic gaps
Report on progress together
"The MS community is diverse, and it spans far beyond Canada. Collaboration is key in making a world free of MS a reality," said Dr. Pamela Valentine, President and CEO, MS Canada. "Connecting the global MS community through our shared focus on a worldwide research strategy will help us reach pathways to cures for MS faster."
MS Organisations Endorsing this Statement:
Associazione Italiana Sclerosi Multipla (Italian MS Society)
Deutsche Multiple Sklerose Gesellschaft (Germany)
Esclerosis Múltiple España (Spain)
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques (France)
MS Australia
MS Canada
MS International Federation (Global)
MS Society UK
National MS Society (U.S.)
Scleroseforeningen (Danish MS Society)
About Pathways to Cures
Multiple sclerosis (MS) is a growing global health challenge affecting nearly 3 million people worldwide. Tremendous progress has been made in the understanding and treatment of MS over the last several decades, but cures remain elusive. Progress will be hastened by having a roadmap that describes the knowledge gaps, milestones, and research priorities leading to cures for everyone with MS.
The Pathways to Cures Roadmap was published in 2022 and includes carefully considered recommendations from leaders in MS research and clinical care, as well as people living with a lived experience with MS. The Roadmap has been endorsed by 30 leading MS patient and professional organisations across the globe.
Research breakthroughs leading to MS cures will require strategic investments in areas of high opportunity and increased multidisciplinary collaboration. The Pathways to Cures Roadmap is a comprehensive plan to achieve MS cures. It is a focal point to coordinate, innovate and optimize research investments.
Media Contact
Laila Namur Manager, Corporate Communications MS Canada
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...
Product: Kalihim (Philippine Bread Roll)
Issue: Food - Allergen - Egg
Distribution: British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...